Gainers
- Shuttle Pharmaceuticals (NASDAQ:SHPH) stock rose 17.5% to $2.08 during Thursday's after-market session. At the close, Shuttle Pharmaceuticals's trading volume reached 565.4K shares. This is 40.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $28.1 million.
- electroCore (NASDAQ:ECOR) stock increased by 12.16% to $0.33. The company's market cap stands at $23.4 million.
- Applied Molecular (NASDAQ:AMTI) stock rose 10.2% to $0.58. The market value of their outstanding shares is at $22.5 million.
- Rubius Therapeutics (NASDAQ:RUBY) stock rose 9.32% to $0.31. At the close, Rubius Therapeutics's trading volume reached 1.3 million shares. This is 119.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $27.6 million.
- Calyxt (NASDAQ:CLXT) stock moved upwards by 7.75% to $0.17. The market value of their outstanding shares is at $8.3 million.
- Lixte Biotech Hldgs (NASDAQ:LIXT) stock increased by 7.25% to $0.59. The market value of their outstanding shares is at $9.8 million.
Losers
- Berkeley Lights (NASDAQ:BLI) stock decreased by 6.3% to $2.22 during Thursday's after-market session. The company's market cap stands at $152.8 million.
- Vyant Bio (NASDAQ:VYNT) shares declined by 5.29% to $0.85. The company's market cap stands at $5.0 million.
- Olema Pharmaceuticals (NASDAQ:OLMA) shares declined by 5.24% to $3.8. Today's trading volume for this security ended up closing at 134.5K shares, which is 110.4 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $153.7 million.
- Erasca (NASDAQ:ERAS) stock declined by 5.15% to $4.06. The company's market cap stands at $609.2 million.
- Rain Oncology (NASDAQ:RAIN) stock decreased by 5.01% to $10.81. The market value of their outstanding shares is at $379.8 million.
- Biofrontera (NASDAQ:BFRI) shares fell 5.01% to $0.97. The market value of their outstanding shares is at $25.8 million. See Also:
This article was generated by Benzinga's automated content engine and reviewed by an editor.